An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas

Abstract

Background: Palliative radiotherapy to patients with head and neck cancer is often necessary, but there is a substantial variation in the treatment regimens reported in the literature, and consensus on the most appropriate schedules does not exist. In order to minimize acute toxicity while at the same time trying to achieve prolonged tumor control, a long hypofractionated regimen has been used routinely in Denmark. In the current retrospective study, we investigated the outcome in patients intended for palliative radiotherapy with this regimen. Materials and methods:Patients with newly diagnosed head and neck cancer treated with palliative radiotherapy of 52-56 Gy in 13-14 fractions twice weekly from 2009 to 2014 were included. Patients were excluded if they had previously received radiotherapy. Data on disease location, stage, patient performance status (PS), treatment response, acute skin and mucosal toxicity, and late fibrosis were collected prospectively and supplemented with information from medical records.results: 77 patients were included in the study. Fifty-eight patients (75%) completed the intended treatment. Loco-regional tumor response (complete or partial) was evaluated 2 months posttreatment and observed in 45% of the entire population corresponding to 71% of patients alive. PS had a significant influence on survival (p = 0.007) and on not completing the intended treatment. Grade III or IV acute mucositis were observed in 25%, and grade III or IV acute dermatitis observed in 15%.conclusion: Palliative hypofractionated radiotherapy with 52-56 Gy in 13-14 fractions shows good tumor response and tolerability in a vulnerable patient population. However, it may not be suited for patients in poor PS.

Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician

“…One patient received CT before RT, and two received adjuvant CT. Locoregional control (LRC) was 45%, and PR was reached in 14% of cases. The median OS was 5.4 months, 1 year survival was 31%, and 2 years survival was 18% ( 36 ).…”

Effect of hypofractionated, palliative radiotherapy on quality of life in late-stage oral cavity cancer: A prospective clinical trial

“…[17] Our results of 36% grade 3 skin toxicity though high was not completely unexpected and was in keeping with the schedule we used and similar to the rates reported in the literature. Even though some trials have reported very minimal toxicity rates using IMRT like the Laursen et al [18] trial, prolonged overall treatment time and possibly lesser treatment volumes (only 20% with stage IV B) would have also contributed to it. Only six patients could complete the necessary 6 monthly follow-up to record late toxicities, and as a result, the data were not sufficient to draw any meaningful conclusions.…”

The Effectiveness Chewing gum versus Cryotherapy on Salivary Volume among Patient with Head and Neck Cancer undergoing Radiotherapy

“…2019). Radiotherapy is one of the three most common treatments for head and neck cancer and requires discipline and a long time (Laursen et al, 2018). Radiotherapy is a cancer treatment that uses high-energy X-rays or other types of radiation to kill cancer cells or keep cancer cells from growing (NIH, 2019).…”